Rituximab and mycophenolate mofetil in interstitial lung disease (EVER-ILD): one-year follow up results of a randomized controlled trial

Footnotes

This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.

Conflict of Interest: A. Versi has nothing to disclose.

Conflict of interest: Raphael Borie has received over the past 3 years, outside the submitted work, grants or contracts from Boehringer Ingelheim; consulting fees from Boehringer Ingelheim, Sanofi and Ferrer; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Boehringer Ingelheim and Sanofi; support for attending meetings and/or travel from Boehringer Ingelheim.

Conflict of interest: Philippe Bonniaud has received over the past 3 years, outside the submitted work, a research grant from AstraZenecca; Payment or honoraria for symposiums from Sanofi and AstraZenecca; support for attending medical and research meetings from AstraZenecca, Novartis, Sanofi, Boehringer, Stallergene; personal fees for advisory boards from AstraZenecca, Novartis, Sanofi, GlaxoSmithKlein, Boehringer.

Conflict of interest: Bruno Crestani has received over the past 3 years, outside the submitted work, grants or contracts from Boehringer Ingelheim; consulting fees, payments or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, support for attending meetings and/or travel from Astra Zeneca, BMS, Boehringer Ingelheim, GSK, Novartis, Roche, Sanofi, Chiesi. He has participated in Data Safety Monitoring Board or Advisory Board for BMS, Boehringer Ingelheim, Horizon, Sanofi. He is the president of the board of trustee of the Fondation du Souffle (a French charity).

Conflict of interest: Marie Pierre Debray has received over the past 3 years, outside the submitted work, payments or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, support for attending meetings and/or travel from Boehringer Ingelheim, GSK, Sanofi.

Conflict of interest: Dominique Israël-Biet has received over the past 3 years, outside the submitted work, consulting fees and supports for attending meetings and/or travel from Boehringer Ingelheim.

Conflict of interest: Vincent Cottin has received over the past 3 years, outside the submitted work, an unrestricted grant to institution from Boehringer Ingelheim; consulting fees, payments or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, support for attending meetings and/or travel from Astra Zeneca, Boehringer Ingelheim, BMS / Celgene, CSL (Behring, Vifor), Ferrer / United Therapeutics, GSK, Pliant, PureTech, RedX, Roche, Sanofi, Shionogi, Vifor. He has participated in Data Safety Monitoring Boards for Galapagos, Galecto, GSK and Molecure. He has been in the adjudication committee for Fibrogen.

Conflict of interest: Sébastien Quetant has received over the past 3 years, outside the submitted work, support for attending meetings and personal fees for advisory board from Boehringer Ingelheim.

Conflict of interest: Anne Guillaumot has received over the past 3 years, outside the submitted work, honoraria for presentations from Boehringer Ingelheim and support for attending meetings and/or travel from Boehringer Ingelheim, CSL BEHRING, GSK.

Conflict of interest: Sandrine Hirschi-Santelmo has received over the past 3 years, outside the submitted work, grants or contracts from l'Agence de la biomédecine; honoraria for presentations or expertise from Boehringer Ingelheim; support for attending meetings and/or travel from CSL behring and Boehringer Ingelheim.

Conflict of interest: Pierre-Yves Brillet has received over the past 3 years, outside the submitted work, honoraria for lectures from Boehringer Ingelheim and Sanofi; support for attending a national meeting from Boehringer Ingelheim.

Conflict of interest: Sylvain Marchand-Adam has received over the past 3 years, outside the submitted work, an unrestricted grant to institution from Boehringer Ingelheim; consulting fees from Astra Zeneca and Boehringer Ingelheim; support for attending meetings from Boehringer Ingelheim.

Conflict of interest: Victor Valentin, has received over the past 3 years, outside the submitted work, support for attending meetings and/or travel from Boehringer Ingelheim.

Conflict of interest: Yurdagul Uzunhan has received over the past 3 years, outside the submitted work, grants or contracts from Oxyvie; consulting fees from Boehringer Ingelheim and Pfizer; payments or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Sanofi, Boehringer Ingelheim and CSL Vifor; support for attending meetings and/or travel from Oxyvie and Boehringer Ingelheim. She has participated in Data Safety Monitoring Boards or Advisory Boards for Boehringer Ingelheim.

Conflict of interest: Laurène Mansy, Julie Mankikian, Agnès Caille, Stéphane Jouneau, Jean-Marc Naccache, Laurent Plantier, Jacques Cadranel, Martine Reynaud-Gaubert, Julien Bermudez, Isabelle Court-Fortune, Mathilde Duprez, Karine Juvin, Mallorie Kerjouan, Charles-Hugo Marquette, Hilario Nunes, Grégoire Prevot, Julie Traclet, Lidwine Wémeau-Stervinou declare no competing interests.

• Received March 8, 2024.
• Accepted July 19, 2024.

• Copyright ©The authors 2024. For reproduction rights and permissions contact permissions{at}ersnet.org